Financials in USD. Standardized financial statements.
A compact view of how GeneDx Holdings Corp. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $427.54M | $305.45M | $202.57M | $234.69M | $212.19M | $179.32M | $196.17M |
| Revenue Growth? | +40.0% | +50.8% | -13.7% | +10.6% | +18.3% | -8.6% | 0.0% |
| Cost of Revenue? | $129.37M | $111.05M | $112.56M | $261.44M | $228.80M | $175.30M | $113.39M |
| Gross Profit? | $298.17M | $194.40M | $90.01M | -$26.75M | -$16.60M | $4.03M | $82.78M |
| Gross Margin? | +69.7% | +63.6% | +44.4% | -11.4% | -7.8% | +2.2% | +42.2% |
| Operating Expenses? | $311.25M | $217.61M | $270.60M | $640.90M | $429.55M | $246.02M | $113.20M |
| Operating Income? | -$11.80M | -$23.21M | -$180.60M | -$667.65M | -$446.15M | -$241.99M | -$30.41M |
| EBITDA? | $6.63M | -$1.26M | -$136.46M | -$398.20M | -$220.75M | -$227.13M | -$22.51M |
| Income Before Tax | -$21.14M | -$52.63M | -$176.69M | -$598.03M | -$245.39M | -$241.34M | -$29.70M |
| Income Tax Expense | -$116,000 | -$343,000 | -$926,000 | -$49.05M | $0 | $0 | $0 |
| Net Income? | -$21.02M | -$52.29M | -$175.77M | -$548.98M | -$245.39M | -$241.34M | -$29.70M |
| EPS? | $-0.73 | $-1.94 | $-7.23 | $-53.63 | $-74.93 | $-33.16 | $-4.26 |
| Diluted EPS? | $-0.73 | $-1.94 | $-7.23 | $-53.63 | $-74.93 | $-146.94 | $-18.48 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality